- Home
- OGEN
OGEN
Oragenics Inc.
as 04-24-2025 4:00pm EST
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | SARASOTA |
| Market Cap: | 4.6M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 395.0K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.16 - $3.43 | Next Earning Date: | 05-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Oragenics Inc. News
OGEN Breaking Stock News: Dive into OGEN Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference
GlobeNewswire
16 days ago
Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial
GlobeNewswire
18 days ago
Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit
GlobeNewswire
a month ago
Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress
GlobeNewswire
a month ago
Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K
GlobeNewswire
2 months ago
Oragenics, Inc. Submits Investigator’s Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)
GlobeNewswire
2 months ago
Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment
GlobeNewswire
2 months ago
Oragenics, Inc. Chief Medical Officer, Dr. James Kelly, Joins the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health
Compare OGEN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OGEN Oragenics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.